Emerging role of mTOR in the response to cancer therapeutics.
Emerging role of mTOR in the response to cancer therapeutics.
复制标题
DOI:
10.1016/j.trecan.2016.03.008
复制
发表时间:
2016-05
期刊:
影响因子:
18.4
通讯作者:
Manning, Brendan D.
中科院分区:
文献类型:
--
作者:
Ilagan, Erika;Manning, Brendan D.
The movement toward precision medicine with targeted therapeutics for cancer treatment has been hindered by both innate and acquired resistance. Understanding the molecular wiring and plasticity of oncogenic signaling networks is essential to the development of therapeutic strategies to avoid or overcome resistance. The mechanistic target of rapamycin (mTOR) complex 1 (mTORC1) represents a highly integrated signaling node that is dysregulated in the majority of human cancers. Several studies have revealed that sustained mTORC1 inhibition is essential to avoid resistance to targeted therapeutics against the driving oncogenic pathway in a given cancer. Here we discuss the role of mTORC1 in dictating the response of tumors to targeted therapeutics and review recent examples from lung cancer, breast cancer, and melanoma.
登录
查看更多内容
影响因子:
17.1
作者:
Elkabets M;Vora S;Juric D;Morse N;Mino-Kenudson M;Muranen T;Tao J;Campos AB;Rodon J;Ibrahim YH;Serra V;Rodrik-Outmezguine V;Hazra S;Singh S;Kim P;Quadt C;Liu M;Huang A;Rosen N;Engelman JA;Scaltriti M;Baselga J
通讯作者:
Baselga J
影响因子:
50.3
作者:
Elkabets M;Pazarentzos E;Juric D;Sheng Q;Pelossof RA;Brook S;Benzaken AO;Rodon J;Morse N;Yan JJ;Liu M;Das R;Chen Y;Tam A;Wang H;Liang J;Gurski JM;Kerr DA;Rosell R;Teixidó C;Huang A;Ghossein RA;Rosen N;Bivona TG;Scaltriti M;Baselga J
通讯作者:
Baselga J
影响因子:
21.3
作者:
通讯作者:
--
影响因子:
16
作者:
Düvel K;Yecies JL;Menon S;Raman P;Lipovsky AI;Souza AL;Triantafellow E;Ma Q;Gorski R;Cleaver S;Vander Heiden MG;MacKeigan JP;Finan PM;Clish CB;Murphy LO;Manning BD
通讯作者:
Manning BD
影响因子:
5.3
作者:
Dibble, Christian C.;Asara, John M.;Manning, Brendan D.
通讯作者:
Manning, Brendan D.